Journal ArticleDOI
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
Aliya N. Husain,Thomas V. Colby,Nelson G. Ordóñez,Thomas Krausz,Richard Attanoos,Mary Beth Beasley,Alain C. Borczuk,Kelly J. Butnor,Philip T. Cagle,Lucian R. Chirieac,Andrew Churg,Sanja Dacic,Armando E. Fraire,Françoise Galateau-Sallé,Allen R. Gibbs,Allen M. Gown,Samuel P. Hammar,Leslie A. Litzky,Alberto M. Marchevsky,Andrew G. Nicholson,Victor L. Roggli,William D. Travis,Mark R. Wick +22 more
Reads0
Chats0
TLDR
These guidelines are meant to be a practical reference for the pathologist and recommend that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question.Abstract:
Context.—Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective.—To provide updated practical guidelines for the pathologic diagnosis of MM. Data Sources.—Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.—There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM,...read more
Citations
More filters
Journal ArticleDOI
Guidelines for pathologic diagnosis of Malignant Mesothelioma: 2017 Update of the consensus statement from the International Mesothelioma Interest Group
Aliya N. Husain,Thomas V. Colby,Nelson G. Ordóñez,Timothy Craig Allen,Richard Attanoos,Mary Beth Beasley,Kelly J. Butnor,Lucian R. Chirieac,Andrew Churg,Sanja Dacic,Françoise Galateau-Sallé,Allen R. Gibbs,Allen M. Gown,Thomas Krausz,Leslie A. Litzky,Alberto M. Marchevsky,Andrew G. Nicholson,Victor L. Roggli,Anupama Sharma,Anupama Sharma,William D. Travis,Ann E. Walts,Mark R. Wick +22 more
TL;DR: These guidelines are meant to be a practical diagnostic reference for the pathologist, however, some new pathologic predictors of prognosis and response to therapy are also included.
Journal ArticleDOI
Malignant pleural mesothelioma.
David S. Ettinger,Wallace Akerley,Hossein Borghaei,Andrew C. Chang,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Todd L. Demmy,Apar Kishor Ganti,Ramaswamy Govindan,Frederic W. Grannis,Leora Horn,Thierry Jahan,Mohammad Jahanzeb,Anne Kessinger,Ritsuko Komaki,Feng Ming Kong,Mark G. Kris,Lee M. Krug,Inga T. Lennes,Billy W. Loo,Renato Martins,Janis P. O'Malley,Raymond U. Osarogiagbon,Gregory A. Otterson,Jyoti D. Patel,Mary Pinder-Schenck,Katherine M.W. Pisters,Karen L. Reckamp,Gregory J. Riely,Eric M. Rohren,Scott J. Swanson,Douglas E. Wood,Stephen C. Yang +33 more
TL;DR: These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on malignant pleural mesothelioma (MPM), which is the most common type.
Journal ArticleDOI
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: The ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up for malignant pleural mesothelioma show clear trends in survival and morbidity and recommend a 6-month to 12-monthFollow-up period for diagnosis and treatment.
Journal ArticleDOI
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
TL;DR: Several promising observations in mesothelioma pathology and genetics have been made in the past decade and are now the subject of further investigation to determine if they can be validated in ways that will significantly impact clinical practice.
Journal ArticleDOI
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Marta Cigognetti,Silvia Lonardi,Simona Fisogni,Piera Balzarini,Vilma Pellegrini,Andrea Tironi,Luisa Bercich,Mattia Bugatti,Giulio Rossi,Bruno Murer,Mattia Barbareschi,Silvia Giuliani,Alberto Cavazza,Gianpietro Marchetti,William Vermi,Fabio Facchetti +15 more
TL;DR: BAP1 immunostain represents an excellent biomarker with an unprecedented specificity in the distinction between benign and malignant mesothelioma and other mesothelial proliferations and is commonly associated with homozygous BAP1 deletion.
References
More filters
Journal ArticleDOI
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.
Babak Sadeghi,Catherine Arvieux,Olivier Glehen,Annie C. Beaujard,Michel Rivoire,Jacques Baulieux,Eric Fontaumard,Alain Brachet,Jean L. Caillot,Jean L. Faure,Jack Porcheron,Jean L. Peix,Yves Francois,Jacques Vignal,François N. Gilly +14 more
TL;DR: In this paper, the authors investigated the progression of pancreatic and gastric peritoneal carcinomatosis (PC) from non-gynecologic malignancies, and found that the survival rates were mainly affected by the initial stage (98 months for Stage I with malignant peritone granulations less than 5 mm in greatest dimension, versus 37 months for stage IV with large, malignant malignancy more than 2 cm in largest dimension) The presence of ascites was associated with poor survival of patients with gastric or pancreatic carcinoma Differentiation of the
Journal ArticleDOI
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J. Bott,Marie Brevet,Barry S. Taylor,Shigeki Shimizu,Tatsuo Ito,Lu Wang,Jenette Creaney,Richard A. Lake,Maureen F. Zakowski,Boris Reva,Chris Sander,Robert Delsite,Simon N. Powell,Qin Zhou,Ronglai Shen,Adam B. Olshen,Valerie W. Rusch,Marc Ladanyi +17 more
TL;DR: It is shown that BAP1 knockdown in MPM cell lines affects E2F and Polycomb target genes, which implicate transcriptional deregulation in the pathogenesis of MPM.
Journal ArticleDOI
A comprehensive analysis of PAX8 expression in human epithelial tumors.
Anna Laury,Ruth Perets,Huiying Piao,Jeffrey F. Krane,Justine A. Barletta,Christopher A. French,Lucian R. Chirieac,Rosina T. Lis,Massimo Loda,Jason L. Hornick,Ronny Drapkin,Michelle S. Hirsch +11 more
TL;DR: Results show that PAX8 is a highly sensitive marker for thyroid, renal, Müllerian, and thymic tumors, and is an excellent marker for confirming primary tumor site.
Journal ArticleDOI
Application of mesothelin immunostaining in tumor diagnosis.
TL;DR: It is found that, in some instances, mesothelin immunostaining can assist in the diagnosis of these tumors, and this indicates that this marker may have some diagnostic utility in discriminating between neoplastic and nonneoplastic pancreatic ductal epithelium.
Journal ArticleDOI
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
Aliya N. Husain,Thomas V. Colby,Nelson G. Ordóñez,Thomas Krausz,Alain C. Borczuk,Philip T. Cagle,Lucian R. Chirieac,Andrew Churg,Françoise Galateau-Sallé,Allen R. Gibbs,Allen M. Gown,Samuel P. Hammar,Leslie A. Litzky,Victor L. Roggli,William D. Travis,Mark R. Wick +15 more
TL;DR: These guidelines are meant to be a practical reference for the pathologist and take into account the localization of the stain and the percentage of cells staining in the diagnosis of MM.
Related Papers (5)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa,Mitchell Cheung,Jianming Pei,Jennifer E. Below,Yinfei Tan,Eleonora Sementino,Nancy J. Cox,A. Umran Dogan,A. Umran Dogan,Harvey I. Pass,Sandra Trusa,Mary Hesdorffer,Masaki Nasu,Amy Powers,Zeyana Rivera,Sabahattin Cömertpay,Mika Tanji,Giovanni Gaudino,Haining Yang,Michele Carbone +19 more